Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Worldwide Offices
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

ACTO'S CXZONE WINS DUAL HONORS IN THE 2025 PHARMACEUTICAL TECHNOLOGY EXCELLENCE AWARDS


News provided by

ACTO Technologies, Inc.

09 Dec, 2025, 13:30 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
ACTO’S CxZone Wins Dual Honors In 2025 PHARMACEUTICAL TECHNOLOGY Excellence Awards -- The First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, CxZone was awarded for AI Roleplay and Field Simulation Excellence.
This image opens in the lightbox
ACTO’S CxZone Wins Dual Honors In 2025 PHARMACEUTICAL TECHNOLOGY Excellence Awards

First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, Awarded for AI Roleplay and Field Simulation Excellence

TORONTO and NEW YORK, Dec. 9, 2025 /PRNewswire/ -- ACTO, a leader in AI-first field excellence solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today announced that ACTO's CxZone won dual honors in the 2025 Pharmaceutical Technology Excellence Awards.

As the first and only AI-simulated roleplay solution exclusively designed for pharmaceutical field professionals, CxZone won recognition in both the Innovation (AI Roleplay) and Product Launches (Field Simulation) categories. Read about ACTO's recognition in the 2025 Pharmaceutical Technology Excellence Awards here.

"This recognition validates our purpose-built approach to develop CxZone, which was to empower field reps to show up in the most human way possible," said Parth Khanna, CEO of ACTO. "CxZone can help field professionals rehearse difficult conversations, test different approaches, and build confidence. By helping field professionals speak the language of medicine with clarity and confidence, interactions with healthcare providers can be authentic in the moment and build more trust."

"The judges were impressed by how CxZone applies AI to a very real and complex industry challenge: turning strategy into meaningful, compliant conversations with healthcare professionals," said Tina Ross, Awards Manager at Pharmaceutical Technology. "By combining empathetic, clinically grounded simulations with seamless integration of current MLR‑approved content, ACTO stood out as a forward‑thinking partner to the life sciences sector and a clear winner across both Innovation and Product Launches categories."

Innovation (AI Roleplay) Award Category

In the category of Innovation (AI Roleplay), ACTO addressed persistent challenges in pharmaceutical field engagement. A significant hurdle facing pharmaceutical companies is ensuring that strategies developed at headquarters translate effectively into field conversations with healthcare providers (HCPs). According to industry data, only 28% of HCPs feel their interactions with field representatives meet their needs, despite substantial investments made in field forces. ACTO developed CxZone to improve field rep/HCP engagement and interactions.

Another recognized innovation was CxZone's integration with Veeva Vault PromoMats and MedComms, which allows practice scenarios to be built around the most current, medical, legal and regulatory (MLR)-approved content, an industry first.

Product Launches (Field Simulation) Award Category

In the second category, ACTO went beyond basic sales skill development to focus on what matters most in HCP conversations—allowing field teams to work on clinical fluency and product messaging, along with receiving specific "Clinical IQ" and "Messaging" scores and feedback. CxZone is built on ACTO's proprietary Empathetic AI engine, making the AI-simulated HCP interaction realistic and personal.

Traditional roleplay exercises can be uncomfortable and artificial for both participants and facilitators. Such "roleplay fatigue" can undermine and limit training effectiveness, especially when field teams must master complex clinical and product information in a short period. ACTO developed CxZone's gamified, on-demand environment to provide field professionals the ability to practice and simulate "real-life" clinical conversations without the pressure of live observation.

CxZone's backend user interface is also intuitive and easy, so trainers can design the HCP avatar, define the conversation, set evaluation criteria, and deploy the simulation to the field themselves in a matter of minutes. Practice scenarios in CxZone can be built around content auto-synced with Veeva PromoMats and MedComms, ensuring field professionals always practice with current, approved materials for their simulations to enhance the HCP experience.

As the first and only AI-simulated roleplay solution exclusively designed for life sciences field professionals, CxZone provides field reps and Medical Science Liaisons (MSLs) a judgment-free, on-demand practice environment with instant personalized feedback aligned to a company's unique sales process and coaching models.

For more information, visit www.acto.com/CxZone.

Visit www.acto.com, or follow ACTO on LinkedIn for the latest announcements and news.

About the Pharmaceutical Technology Excellence Awards

The Pharmaceutical Technology Excellence Awards is an independent recognition programme powered by the business intelligence of GlobalData. Its team of researchers and journalists, along with Artificial Intelligence, analyze over 1 billion datasets during the year to recognize, endorse and rank top-tier companies and their achievements in 200+ counties. One of the largest and widely recognized programs industrywide, its objective is to recognise forward-thinking, innovative companies that drive positive change in the industry. The program focuses on Areas of Excellence in business expansion, diversity, environmental, financing, innovation, investments, M&A, marketing, product launches, research and development, and safety and social.

About ACTO

ACTO is an Intelligent Field Excellence (IFE) platform built for life sciences that unifies human intelligence with empathetic AI to help Sales, Medical, Market Access, and Marketing teams improve customer engagement and brand performance. With ACTO, biopharma companies can ensure field professionals are always competent, confident, and credible in face-to-face HCP interactions, while providing senior leaders and frontline managers with the insight they need to drive continuous field force effectiveness. As a validated platform compliant with FDA 21 CFR Part 11 and SOC 2 Type II certified, ACTO is the trusted partner for intelligent field excellence in the life sciences industry.

Photo - https://mma.prnewswire.com/media/2841285/ACTO_Technologies__Inc__ACTO_S_CXZONE_WINS_DUAL_HONORS_IN_THE_20.jpg
Photo - https://mma.prnewswire.com/media/2841286/ACTO_Technologies__Inc__ACTO_S_CXZONE_WINS_DUAL_HONORS_IN_THE_20.jpg

Modal title

Also from this source

ACTO UNVEILS ACTOVERSE: A PARTNER SOLUTIONS MARKETPLACE DRIVING INNOVATION AND EFFICIENCY IN FIELD EXCELLENCE AT VEEVA COMMERCIAL SUMMIT EUROPE

ACTO UNVEILS ACTOVERSE: A PARTNER SOLUTIONS MARKETPLACE DRIVING INNOVATION AND EFFICIENCY IN FIELD EXCELLENCE AT VEEVA COMMERCIAL SUMMIT EUROPE

ACTO, a leader in AI-first field excellence solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today ...

ACTO LAUNCHES CXZONE: THE FIRST AI-SIMULATED ROLEPLAY SOLUTION BUILT EXCLUSIVELY FOR PHARMA FIELD PROFESSIONALS AND INTEGRATED WITH VEEVA PROMOMATS AND MEDCOMMS

ACTO LAUNCHES CXZONE: THE FIRST AI-SIMULATED ROLEPLAY SOLUTION BUILT EXCLUSIVELY FOR PHARMA FIELD PROFESSIONALS AND INTEGRATED WITH VEEVA PROMOMATS AND MEDCOMMS

ACTO, a leader in AI-first commercial learning, enablement, and customer engagement solutions for life sciences and a Veeva Product Partner and...

More Releases From This Source

Explore

STEM (Science, Tech, Engineering, Math)

STEM (Science, Tech, Engineering, Math)

Computer & Electronics

Computer & Electronics

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.